0001493152-24-018175.txt : 20240508 0001493152-24-018175.hdr.sgml : 20240508 20240508090042 ACCESSION NUMBER: 0001493152-24-018175 CONFORMED SUBMISSION TYPE: 10-K/A PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20231231 FILED AS OF DATE: 20240508 DATE AS OF CHANGE: 20240508 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Strawberry Fields REIT, Inc. CENTRAL INDEX KEY: 0001782430 STANDARD INDUSTRIAL CLASSIFICATION: REAL ESTATE INVESTMENT TRUSTS [6798] ORGANIZATION NAME: 05 Real Estate & Construction IRS NUMBER: 842336054 STATE OF INCORPORATION: MD FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-41628 FILM NUMBER: 24924452 BUSINESS ADDRESS: STREET 1: 6101 NIMTZ PARKWAY CITY: SOUTH BEND STATE: IN ZIP: 46628 BUSINESS PHONE: (574) 807-0800 MAIL ADDRESS: STREET 1: 5683 NORTH LINCOLN AVE. CITY: CHICAGO STATE: IL ZIP: 60659 10-K/A 1 form10-ka.htm
true FY 0001782430 0001782430 2023-01-01 2023-12-31 0001782430 2023-06-30 0001782430 2024-05-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-K/A

 

(Mark One)

 

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended December 31, 2023

 

or

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from __________ to __________

 

Commission File No. 001-41628

 

STRAWBERRY FIELDS REIT, INC.

(Exact name of registrant as specified in its charter)

 

Maryland   84-2336054

(State or other jurisdiction

of incorporation or organization)

 

(I.R.S. Employer

Identification No.)

 

6101 Nimtz Parkway, South Bend, IN 46628

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (574) 807-0800

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered

Common stock

Par value $0.0001 per share

  STRW   NYSE American LLC

 

Securities registered pursuant to Section 12(g) of the Act:

None

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer Accelerated filer
Non-accelerated filer Smaller reporting company
    Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.

 

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.

 

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

 

Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Act.) Yes ☐ No

 

The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant’s most recently completed second fiscal quarter: $38,040,290.

 

As of May 8, 2024, there were 6,440,509 shares of the registrant’s common stock outstanding.

 

Audit Firm ID   Auditor Name:   Auditor Location:
400   HACKER, JOHNSON & SMITH PA   Tampa, Florida

 

 

 

 
 

 

EXPLANATORY NOTE

 

Strawberry Fields REIT, Inc. (the “Company”) is amending its Annual Report on Form 10-K to add Management’s Annual Report on Internal Control Over Financial Reporting to Part II, Item 9A.

 

Current certifications of the Company’s principal executive officer and principal financial officer are filed herewith pursuant to Rule 13a-14(a) or 15d-14(a) of the Exchange Act. Additionally, because this Amendment does not include financial statements, the Company is not including certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 
 

 

ITEM 9A. Controls and Procedures

 

Our management, under the supervision and with the participation of our principal executive and financial officer, is responsible for and has evaluated the effectiveness of our disclosure controls and procedures in ensuring that the information required to be disclosed in our filings under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, including ensuring that such information is accumulated and communicated to our company’s management, as appropriate, to allow timely decisions regarding required disclosure.

 

Management’s Annual Report on Internal Control Over Financial Reporting

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting. In May 2013, the Internal Control – Integrated Framework (the “2013 Framework”) was released by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”). The 2013 Framework updates and formalizes the principles embedded in the original Internal Control-Integrated Framework issued in 1992 (the “1992 Framework”), incorporates business and operating environment changes and improves the original 1992 Framework’s ease of use and application.

 

Our management assessed the effectiveness of the Company’s internal control over financial reporting as of December 31, 2023. In conducting this assessment, it used the criteria set forth by COSO in the 2013 Framework. Based on management’s assessment and those criteria, management believes that the Company has maintained effective internal control over financial reporting as of December 31, 2023.

 

Limitations on Controls

 

Our system of internal control over financial reporting was designed to provide reasonable assurance regarding the preparation and fair presentation of published financial statements in accordance with accounting principles generally accepted in the United States. All internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance and may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

 

Changes in Internal Control over Financial Reporting

 

There was no change in our internal control over financial reporting that occurred during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

PART IV

 

ITEM 15. Exhibit and Financial Statement Schedules

 

Exhibit   Description
     
*31.1   Certification of Chief Executive Officer, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
     
*31.2   Certification of Chief Financial Officer, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
     
**32.1   Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
     
101.INS   Inline XBRL Instance Document
101.SCH   Inline XBRL Taxonomy Schema
101.CAL   Inline XBRL Taxonomy Calculation Linkbase
101.DEF   Inline XBRL Taxonomy Definition Linkbase
101.LAB   Inline XBRL Taxonomy Label Linkbase
101.PRE   Inline XBRL Taxonomy Presentation Linkbase
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

* Filed herewith.

** Furnished herewith.

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  STRAWBERRY FIELDS REIT, INC.
   
  By: /s/ Moishe Gubin
    Moishe Gubin
    Chairman and Chief Executive Officer
     
  Dated: May 8, 2024

 

 

 

EX-31.1 2 ex31-1.htm

 

Exhibit 31.1

 

CERTIFICATION

 

I, Moishe Gubin, certify that:

 

1. I have reviewed this Amendment to Annual Report on Form 10-K/A of Strawberry Fields REIT, Inc.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

  By: /s/ Moishe Gubin
    Moishe Gubin
    Chairman and Chief Executive Officer
  Date: May 8, 2024

 

 

EX-31.2 3 ex31-2.htm

 

Exhibit 31.2

 

CERTIFICATION

 

I, Greg Flamion, certify that:

 

1. I have reviewed this Amendment to Annual Report on Form 10-K/A of Strawberry Fields REIT, Inc.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

By: /s/ Greg Flamion  
  Greg Flamion, Chief Financial Officer  
Date: May 8, 2024  

 

 

EX-32.1 4 ex32-1.htm

 

Exhibit 32.1

 

Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

In connection with the Amendment to Annual Report on Form 10-K/A of Strawberry Fields REIT, Inc. (the “Company”) for the fiscal year ended December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Moishe Gubin, Chairman and Chief Executive Officer of the Company, and Greg Flamion, as Chief Financial Officer of the Company, each hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to their knowledge:

 

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

    /s/ Moishe Gubin
  Name: Moishe Gubin
  Title: Chairman and Chief Executive Officer
  Date: May 8, 2024
     
    /s/ Greg Flamion
  Name: Greg Flamion
  Title: Chief Financial Officer
  Date: May 8, 2024

 

The foregoing certification is being furnished pursuant to 18 U.S.C. Section 1350. It is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, and it is not to be incorporated by reference into any filing of the Company, regardless of any general incorporation language in such filing.

 

 

EX-101.SCH 5 tcbp-20231231.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 6 tcbp-20231231_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] ICFR Auditor Attestation Flag Document Financial Statement Error Correction [Flag] Auditor Firm ID Auditor Name Auditor Location EX-101.PRE 7 tcbp-20231231_pre.xml XBRL PRESENTATION FILE XML 9 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Cover - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2023
May 08, 2024
Jun. 30, 2023
Cover [Abstract]      
Document Type 10-K/A    
Amendment Flag true    
Amendment Description Strawberry Fields REIT, Inc. (the “Company”) is amending its Annual Report on Form 10-K to add Management’s Annual Report on Internal Control Over Financial Reporting to Part II, Item 9A.    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Dec. 31, 2023    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2023    
Current Fiscal Year End Date --12-31    
Entity File Number 001-41628    
Entity Registrant Name STRAWBERRY FIELDS REIT, INC.    
Entity Central Index Key 0001782430    
Entity Tax Identification Number 84-2336054    
Entity Incorporation, State or Country Code MD    
Entity Address, Address Line One 6101 Nimtz Parkway    
Entity Address, City or Town South Bend    
Entity Address, State or Province IN    
Entity Address, Postal Zip Code 46628    
City Area Code (574)    
Local Phone Number 807-0800    
Title of 12(b) Security Common stock    
Trading Symbol STRW    
Security Exchange Name NYSE    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company true    
Elected Not To Use the Extended Transition Period false    
Entity Shell Company false    
Entity Public Float     $ 38,040,290.0
Entity Common Stock, Shares Outstanding   6,440,509  
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction [Flag] false    
Auditor Firm ID 400    
Auditor Name HACKER, JOHNSON & SMITH PA    
Auditor Location Tampa, Florida    
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 3 39 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://tcbiopharm.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form10-ka.htm tcbp-20231231.xsd tcbp-20231231_lab.xml tcbp-20231231_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form10-ka.htm": { "nsprefix": "TCBP", "nsuri": "http://tcbiopharm.com/20231231", "dts": { "inline": { "local": [ "form10-ka.htm" ] }, "schema": { "local": [ "tcbp-20231231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "tcbp-20231231_lab.xml" ] }, "presentationLink": { "local": [ "tcbp-20231231_pre.xml" ] } }, "keyStandard": 39, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 3, "entityCount": 1, "segmentCount": 0, "elementCount": 64, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 39 }, "report": { "R1": { "role": "http://tcbiopharm.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorFirmId", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorLocation", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorName", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r11", "r13", "r14", "r16" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r20" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r17" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r18" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r19" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r20": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 17 0001493152-24-018175-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-24-018175-xbrl.zip M4$L#!!0 ( !1(J%AV02P#I0< XO * 97@S,2TQ+FAT;>U:[V_; M-A#];L#_ V=@0PK8<9(VPQ![!IS8W8QE39 : _:1DBB;BR2JI&3'^^OWCI1L M^4?3='/6='.+Q)%$'N_(=^\>:75_'O]ZW:O7NC\/^P-\,OK7'8_&U\->M^T^ M\;1=/.Y>W@Q^9^_'OU\/?VR$*LDNV.E)FK&QC(5A[\2"RW# M!CJBZVW9+Q,/68M'>BK+5(P[C=YWB6?2 M3K=]NV'LJ4Z4-F$,39<_Q^GQZ?=]B6FELSW]A[.>BANEQO39B4SX33(N9%',18%&D8?U8) %^,I8IUD^2G$?L M3J1*9TPE[*W2,2RT?FGWF0K9^TSSN2>T7K"W4D2!87?#T;C)1HE__&QS M3[M_AN6]Y :+BD6+%^P^4?-(!!/1=*NLW8H&"E83E3$?!KA,&$\6+$\RG0MF M,IX)"P0L-$<(,Q(ZK%- @U\*7V\QC-$O2'*X'0;#Z5_I29G'ZM^L^%%H41BB"6)A(\D,F$ MS64V180F%;[U$';KM13.J0"!SM O8-ZB.A$'K'Y!K+Y^#*N"A3(!& A8J\5O M JAHCL>Z\EPF(>B)9Q)V9.)'>0"; %AEH9M I]31@J7 !V&;,!]%2_#6:P5N MS,;82)! DN4F(2N/T "(54"5'<]8AWQNIBR,U-R4<-9B(@U($B-QNNDU"P&YQ+OTG4@C1\IDZ,?L;%6D0-5JI4O MP& M*(X HD E0XIPP=_RI.)8'T0W5T>(;K3U[QU>GXDG!NGYX&[2]&GBT$P# M,"+#"L@=YLB91P:JU]9&"M=&"C$21;J)?;0@K7&0?)LA['2ZN"E1_FZ=WH>KK"2"I&,G5@O@G^?RC=@='8&'*5[/?7X#V6$MY413V;+K<1X.L_NRH]Z M;3-!J!F2:B8#@CTW*N%44KA!RI!0IES@.BAAB4R1W).1S!:D0W:-2VEJ$6S! MZ1)LK>E*:]5KMG0]%"&EN4Z1'<8J)]]7.K >6,T]$0GT4(0DP1.14OI1$VPH M7"(@366*VG%(A1>="CY283CC46X)E& BPA":6,ZPOF:'MEW*HB=4!'>Y(7=+ MTB3@HR/(G' /Z'%/Y=G'77A*T>++UH+V#&&5N7?O!IE7[D9L-@LW%7"H X>2 MX #>EPS>@'CS="IC3VFK(@D7R7N##GM-L=&C^XTGJL$/*O,"][?D_V=O:8^.@3++F MBB^)OZLX7U$G(74G9B O=BFJ+9&_=(]#Z&=*FZ6&L3=@,XYEE@GQ2'GR%%02 M/0\D'+1&CI -* ;&5AO\0?N-,HO%AUPB )NP>>+;32CP*ZD.KH E1"4#>=?C&(WN0Q9AIAVVB**K;SQ/.@3?9' MM,\?E-UN]J%&0@WZ:@)+PK(NT&B_S"A@VW2U7"8S%#J?*D?-?"TI .)'Y$Z]]F3$'_^WOD8?]R^OA^QJ>'W]_K9_-7KWTX^- MDX:]ONT/!N7U9T[GCPMQT^/_GV&>=\/-B'BWOU\')Q\:A[Q=J5KR=Y$??O MV>DQF(#9XT5G\K,">+/?"+JC7MNTG>/5]RRZ[5&O&AI^W;T4O+U0C/T/W%I' MR $=![>J;EU-N8243*S0O)I*$;+A@_!S.G)C-VX'>$#-%W-K $7X>+GZ(I3" M%^R')CL[.7NS&QMM*[)Z7[M67/U?Q;'TKK&2E-^T6NY%N MV"Z'>P2@?VQA.>:Z1VO8I?S7L*GA$ZWC>DI9ZHROVV: M8#>)GUJ5-KW/[EYPI_?@_P)02P,$% @ %$BH6-AU2=V?!P FBX H M !E>#,Q+3(N:'1M[5KO;]LV$/UNP/\#%V!#"MAQDC;#$'L&G-CIC&5-D!H# M^I&6*)N+)*HD9=?[Z_>.E/R[:;(FJXNY16)+(H]WY+MWCXQ:OPW^N&Y7*ZW? M>ITN/AG]:PWZ@^M>N]7PGWC:*!ZW+FZZ']C[P8?KWJ\'D4KM.3LYSBP;R$08 M]DY,V9U*>%KS-VKLO= R.D!'=+TM^UGQR=9Y+$?I.0M$:H5NLH3KD4SK5F7G M['A^.536J@1W#MH_I4.3-5N-VP>,:3D:VR9[K%_E,+"/IO.?@W;KZN;=8#G* M>L03&<_.OV3/M37R;^&'AZ6+=N_36 ZEK59>GQR=MAH7F%8RW]X,Y2O];K+- MB7W.6,H5^#Z]QTI<]NX&_:O^96?0OWFW7XG'>?]7;JR,9L_I?K]6K;S58L2N M8EA0Z! (38,P.^;V_*7B.CJ3Z8O']ITOSIFL8B'(F:7V7M5S14L)HJRP(8 MX#)E/)VQ/+4Z%\Q8;H4# A::(PYPFP08(A[@EF8JD0XCKMU&@U0$PABN9]4* MVB3\7F#@):,&]T)X@S%C*N8T"#4(I [R!,U2](RX6QY(O98_898??T0 M5@6+9 HP$+ 6BU\#4-$U!E6@4BQ&V XA @"@50Z9'2^Q2,>3H2K .BN\MC1'?RFM=/S@Z%=^/D M+/17_E*2/DT]FFD 1F2X!'*/.7+F@8&JE961HI61(HQ$D:YC'RU(:^PEWWH( M6YTN;DI4/S)Y?'2*\)XSDD/^JEKI"H-!L<"NLGX9?C6J^@'/S>.[4/4="B"I M&,G7 MDI<.1VR/N,V,R(X49& M/)HM-Q+C\3R[+3^JE?4$H69(JHD,"?;$&*4-"F7*!Z["$)3)%\J&, MI9V1#MDV+J6I0[ #IT^PE:8+K56MN-+UJ0@IRW6&[#!..06!TJ'SP&GND4BA MAV(D"9Z(C-*/FF!#X1,!:2HSU(Y]*NQT*@1(A=Z$Q[DC4(*)B")H8CG!^IHM MVG8NBQY1$?SEFMPM29. CXX@<\(]H,>'*K>?=^$Q18O/6PO:,T3+S+U]-\B& MY6[$9;/P4P&'FG H#??@W67PAL3C'A:;^*+CC4+)NB=;0?P$]B:QHH(@UP2B M)6&P:;5:292Q>$"'Q#!F ECZF$-8P/;A9SR)D ^@U;76A>?8; IW-$.G-NZ8 MSCOVRKLUYF:NHXB07?J($&(+;.YFI*@C,Q;+>X$/=TZSUJ'VU9/49/N4V<&] M[=G7[&W=L7%8)EEMP9?$W\LX7U G(74K9B OMBFJ#9$_=X]#Z%NES5S#N!NP MF2326B$>*$]#!95$ST,)!YV10V0#BH%QU09?:+]19K'XF$L$X!(V3P-WSO-J MOX7=$:*G+6PGAE+%L!( I7,&.K((I ":"J4QWTE.!;\GY>"%J],.3G2[D^SR M%.^S(-W*_G[/AZT='=9M(5,>HJ<1=COI()0.X#&J=:>33,C_XWD!IT+JY[[+)W??W^ MMG/9?_?VUX/C W=]V^EVR^LG!S^5H1U3T^,?FZA &CO\>J#BF&<&#I7?#MPK M.:W!W=,'F%"EAD LI]&J[*!XP:@N^E>,3'E>T## MF ?W[.0("\_<6=Y37O8I GCSO!&T^NV&:7C'EU]J:#7Z[0=#>_K,'S^KXVMH MAXOX=;'O92'?"K=578"['4D3L:LZT-UY=LYUS^_^#FRXJ[_GN+< ??,9^ MJ;'3X],W.^?;0^!HN$K:WK]G]Q+OF;ZE/V?7W%A6KY>9U>W_N6IT+DM^IJW#FE2Y6)EX[JT7)4^FYIP33MN3L>"A;=PZVK.Q")R/>:DL6)ZX]WJ14J4F5UF M=:N!Z2EG:FE^&S3!?A*_M"H->K?A MV8@U."RB"L[I+5R)B/!J=J(*UU2RH((+<>EEL4[3.UTC(9OP-GB4:RH[$!$Y M8;RF1=R&QOS0%5J+",]4NGO<57''MBY7A+T41"$3A>'4^:?2M4\OSIU%:;6 M1"RM M>M.V3C:FSK(J&0'6J4O!E#6ASSD9ZX>L-.PU_UZWJ_CMMZ M1BHT#X\:5>@IZ/DBUM1?FEY,^MSX!+B[GM)RZ9I(EW"J:A=W(9U!S]-FJ-5H MM#;)G(>!L/7L>9+[/Q*%KIVM$_X(*>()SG.?W3(]-1Z#7D2YCY_4HSW.$^3& M%8V%1,=Q.!4R0@&U/ZV>\>.UEN36I5+.D$DT]!5<#4=.%4;) MZ/1%%!,^VY/IT0'"D>EN 5,>"& M.#9'B51+)-,,539D'MYY4\(G%'"?B"EE-,)?,],GFL*42HIP%Q%E.A6 JG F MF#*$_9JX#*W7GQ(FT8X+L?(PCC*20ZY<-9W[5=()G(;H%<%3Y+\+M-7%E'C3 M%*@[0\]DL6P<&+\@('$;D@=D_&1 PN_CL8KC)%V&\YB$GUS5 N.>C#/!R#) QGX"%_0A,'\]B0]"9A MDIH85FF0SJFR3PX Z]YM.\?S EQ'TGS*,I9T?Q\^+%C2/WF!%BQ9:N%QHS7 M6L?\CVC1RFG!.&;5*+WZ(RNX)HQC/F!9&BPX@UD-21-+J@P]JF:8A"%J@5=' MDYUP($:^J&J>GHNLA0)]EHHV20YG)6'&+A%3F>ZITI)C(:75WX V;\X0IW;N M*XI_-R3>3VC6D9Z@1,C\3.JK=/BX7B7L4==25@8\JWL@+7ML:]1=5 W_7&T+ MY;:49NN$=4ZBA6)K6U M$V1'CG>"Y3 =;B$[7G*?M&/-N\$:8%VW?:0Y(S,X M3F_N/^ZXL8/U'*P=+[8-UOI*W/67M>D3N QQ_AAN5];NRMH'J!:?T^[(L2MK M5\O:QQ_:[YBR*V5?5\I:Z1/#[JYM\J;=3<>T\@*!.5XP/@%OL34.3(%+S>D@ MD=P\W/!?T&2KPTB;E5SH8G7:DC2=3%P="T67NRW']SWPIULL6?LN2KN?5=.? M$;A*WC)%027N#Y27-^4@9,1E(=.S3#3!:BO;+6L]LCE G.^:AH G$)C$P/'+ M)7<&D@944NZ9(9Q"^,PH8719;4:BX8CT0ZI2G548B:\%VJT#%&9A$R, M0 3K37-Y&WOT_SZ\7U1@#JMRK]T?M5K6_V[#)1JC@])O$F-GE-J!BSAMC[1A M3)2&6JU(7(/1W\M"Y_7T)]-+6JFQ3U9K;-S_OAFQV'Q8;4XLU^P/NPHKW8>' M9?7]Y>V1B]:R1T(:I"OF.7E)]"-O)A7V+G)FD2]M"\U36&K!OI8Q<&;$Y[QB MF5?0LG?2S*MK_P)02P,$% @ %$BH6% .9^9?'P W 4! T !F;W)M M,3 M:V$N:'1M[3UK6^+(TM_Y%7TX9\\Z^\HEW!1U/ \"*B." S@SSA>?)FD@ M&A+,16%^_5O522"!Q-L$!Y39W5E-.MU5W5755=55U0?_&P\5Q@X$)S:"I:GR.#TQSM)=*/3P\)!^R24WO MIX1BL9@:8YNXW6AO'-@NDTX+J1_G];8X8$.:D%7#I*K(IA\ILGH;WC^^G3;M MZHKL:XI/W$&RJ86NX:TT^\#;N)"R7_J:FH%-\W93TVTJ&UHN(^P\!H?=8OK! M.*RM@# #ANS'4:L^:VX&MY\U39DZ58V>I@^I"4N(/>43Z4PB4_!TDC"8Z.L( M?D_VM?LG^]E-9 6WGX7%\6.*K[O4F,ZXQ.:FVQT37L 7F:S;4&>]T&X+*7CK M-K2,1)_2T;1QCQI=WM!YX>L5GNF:PHS UOR-K[FH6:JI3X(A=E[Z/C!T<[%K M>.AKU"D?74Q;F6)7UD8#J@^3HC;D[03X-X[)_4*OR'ZW2F?'W9_BM3.2F5+N!_"!A)))[Y<;9T MC5A>^[&[=K%[?D>Y$O\H+:2%5WR=SU\S("P '_XM#9DJP7_FL4+[UZ9NL1=T M5/)T5-%$B_T&7:TV55A86=E*%3G2HU56+C,S:Y M3H-@W-G-Y++IYW=;.()EJUP+UXZ,L?N'1R_H(G/=AB5CQG7FFDM4NP^#/WM! M-Q6$Y,+I*KL 4%C?74V:$,.<*.QSO =TO$>$],@D'7D(+1KL@;2T(56W[0?; M,+XN]Y!=)/G>_4R2C9%")WM$U52&[^3Q'I(^TX&?^"^R)#$5F0M_@U8-6%%= M%FW&&9LME#['NC9$FDND!?C7U/C/0H8+/UF"]U0TT_@'.%N%"8!QF;SG([/X M(=+90\-^-X HF64<$5">U"1+P<]R0AR.%H=1SAO'U M; ]E:);NC 2-.#GN.1-A(QH^$8Y<=K]B''GWX?2Q+.&+GLQTPI%@@=MMN7;F MGZ?YCZ>#I8)&<\8:\25? $4'MVL4),=SC!Q^YF]F_\*2'CV#<=X-K;D_<)] M[!W=?>9,9>CTEHQFSP:JD,BFUV=*;2W2/)S!/NW?>1/=Y.02:52XUG)R'-@C MFAQ+E>V9@:UC?CJ&C!J6S@Z=+68/FKA=N:]\_6-?P9W;NU58_P[;\#:O'&"V M)QB+Q0Y&+]4;]@G268(J[/=",C]KX<7"BP0NA?.W!X>4#XFU72G_ M&JTG#D'4]@I,;" Y=+/_@A","/9=/@O=P\M&K5.MQ-J=4J?:/DAU?W]-_A0F M[6KYLE7KU*KM6*E1(=4?Y=-2XZ1*RLWS\UJ[76LVUA*]C(/>=VH,9+5O:NIV MK)(L)TDFG<\5UQ*E]\ WQ\W6>IPF7I< MKG\-"E_&^K@FYK0,=/?[MJ.0#C)>N?/J4$@GSE*E>7-Q.O,; EJ$/4HXM\ZI M?AMKJNS3ZL,:-*D>SLN*W3E945)5BRHM-M)T,UAF M_*KKP@TK: M)^RKY6)RK.DQ<\!(CWMUR811G3!58A*99\^=.?:T/0Z 0A9>H)4M79^ZMZ^@]T=1,T9G M-^=JOD0O:9SP,[//<:<'8G=!L \"G1!GW&CQ7\#=YZP/0R9^6&$B&W:93M#C M&BBJMA>6OC"W]+-N[5.IP!D2C[Z/S.97W9CTHE'H\N&G$5-0XMQG&BJ#0QYO ME+VWA5W3UQ/NC3+X9LI@=MYPQ# 1&4-$'E,(C=O;^UJK)DZ&V2@5PAY5C'F- ML!!H7LY!Z6B%N?>@%79:I4:[AJK?1C/\2)JA.:5I8I^DD1YP#[F>_@&QXOGM M_4CV]5RVLC8[9V MH]!H%+F=Q:B.&0QX<"PD&('[9AT_I^5&VUKF+'M6J]TH9MJ];9)K5&.?GN MW+];U3%,30SGA&@]HD_G@E"#&",F8NB%1&181M,@XH#J ,"27+#O4Q.?'EN+ MFJ+0D0'@N#^]5DG_'7U\7KVW=YDIQ+GB7\M>A@#!D/,)AIHJ:CIHPA3UA[9) M35:V@YK+FA0B)VY;9]KYW5=!>A"CT.$Q!AWCT$PVTK5[9(X%STEQ49 \"G?\ M\)SJ$X6JTINJ]>YQ?H!5-UWSS%]+Y++?PF0EB;7D(]8.'=><$#61+_QC6M&= M?'9UY2+:S3'J1"D, BA_NYA*9;+:0SN>>28%3@^IM)=1SR-Q2?Q_5$4^MQZ&6O7.0(ZWVJRK_X M[UY=XFWDWJH*NX] ][5D*]E.\CFJ#D>*-F'Z.Z%UO\SEF( 5O4#=&R?5GU^J M@#T][=O32Y*D,\-P_E>7528$[^>YZGFCT7P0*8W&RY$1%O?S &#BAP4 )-:0 MA^8O?:Y7"4(U3+\V-0[VH,:C.AYK:P*E>]F_D2.!M%,**(S4, 4 MURQS0(Y8J-*\B%XY"#V^W3;U"U#F83,*L2%^#)NJ:&J-H1B1 MC1 $%_"K!N%WH8&QHOR41^$6TF7OY\WMY N]Z403*I?)A6+G@R9^F"L\YI:+ MS''R9S]$$.&1\ 0[>X8$H\SNY3\^5*RX&=0T3-7$2'C-DSTXF@X?+ MPL]?W=?[6WQH^$Y&YV$ VS6]DTCOIA>R-=?>_[JF'GX.>QNDFRZ;,C-BMM^8 MZ4PB(TLW+'0@FQI\RF/1EV-67+^+3N\Y8M+'W>\-S01W!L+ ZHV@>]3R4/ QF>S 1D1![6 MR .U J=H/56[,)O)V; F0J;+A41(#&JSV/TF78G">"<:W<87NC /@QU\H:DQ MP]3$VV=$+Y H_ZSI E]0G=Q3Q6+D/^DDGL9AE!'A&=]/N9.# 'M$(/W^6=7; MDKH;I>.(U*T="Y+[;"!P /JOC^%'%_O-4ZFA-,56?? M" ^(.:H>E3OU\OA[HQO903?N5D%GW)EBD.#RP@A;WU6[&K*N?'%*_!$@7:^7 M'PW6]%@!3Z:C+XJ<&56,?L>E_AJAMLX^D!=9&%8Z+JC!I%83U;MZ#6L]$%RZ;Q+PC/*1VI.DBOXP0F[#TUBLYW< MWV',,QRR[8Q8XP,&B^M>NM20F%(J2-&3F($R_,L!F),?^-I%S/I_C@_^$\0 MOVF*I9I4Y^'8>DA>7Z%\6KVZ.Y&*WZ(Y6\L&')3. ;*A__=)_P\#QN.EYIA@ M2_A$!B#SD?(E0A5E2OY>ON@RIP'TZ6<%'PMX=@=7W8T!6^!KS#PB$KQ5^[SI M2&.*'5UC<[5'V)@V- M3%/I-IS^7C@=.0"(?RB;)K +4X )=$U%8UZ9$ :&_8344-$&FL*C]PHU*3FV M]T.?()CUX=T@45&,.8IBB_4MQ8Y:;"*;,SX],B*U?G NFGTX"SX'!2,"N;H]V=.@.MD6:L&\C=&AF32^V$0\M?"OMLL MM$',:; GPN VQ%N\D[;$%#=EJY)*V2ZB8RKMKBZ"E?AETI5;\L2[_F,_>7G MF>E(TW7JP;0=34B["W(VX@PC_T80"8C1)D&5ECJ?^65/Y^J<2R_S]$58R&C7 MR[!B?4V?!.M(WW+WW<'5E]I=]R:ZPQ<^.*<1T1E\_APF&Q!JZX,671T!6^(K MSMO^Q++,.V-6!*QVV&:]:H ^'@'/T3BR#%EE1H@5W[K1K\KBKQ_CN]<[YYY5 M$3$;<#6'#[ZG"R*^=QD574+9^X>J&JPBKQJ8C[O/721.. YE&X40)WJK+@[9 MB7[64Y;,IX5%/@V$\U7\NN3,MXWM_FK;O1<+MY$Q%\(V[U6BS"X,&,VCQ M_.)FH.TTE;O7IP,^KY)<-J 2V[C25I@=7^P5=\Z^')45@X_1H41- MDV$M$V0!X :LXP/#TSX_(W)SGP@U#%# \)'+(:S78]Q7JSJ);?BEC"Y<%=@/ MZ5G7%**!*N7ARIFV;,'$S$Z8<^F<)P6D3?4NA6X3S;'")LB"9$O(D\MD&Z]D MV,D4,%_D$PJ:&988FA0;65T%F,G#^SU9']KN\Q&,3=%7#N*"!X%('&)J2;+I MP+7(Z*ZR7!-[>@E;:GII-E_\3L9 5L]?YH_4=*[^XU)8-JO[PBK#X=PP^UHS M>R]FS Z=@8S)"U.J0O=GK[R8\2DO;F0?$FOS&WC,SGJT Z?LSYRCY9["3YSA MD:CIN@,)?(]J@Z[C8;.&;'@O:Y:A3%PN#!IUD1/S"_6BU;8Y-*O8;WDZ6CA' MEJW;GS_JW8=11.0=IH.+:3##C M#9>3/=S&MZKIL2[NU:+&SZQA2U8FALSY$8L"J+CU)O"6:HGKQ4PUN*R/X=$R MO.(Q+-/1O?P[W=/G\\]UPWM&K8..?H]290J"HXE[Q8USY)U+)X5T)2& S$EN M#F+7 :-7',0: Z8HKKU'MCP!M-#'XFDC&DZ??(&"#6U!JON+I;5Q!-?'(76/ M@R7Y0[EG_+KZEFM^6[8DSP6$TWIA?+9_XQT0S)]F@>@E=V? 8K3?!S)'K0C) MGYE.VIA#PO<:MR'02L*@ N=7D2?D$931YH0 .7 &X%$'/52%H#>#LXEEVKPQ MO<09):8=_@/2%@PO._DS9BM,WDXQMD?!H#Q#4R0>G8!M*$AAO(RR*TNVY6;< MHO;'.P.(>>2/KQ\>Y>[@PKOK.HYTC/0+WQAB0\W@8A\F'M0T[G5AB NHH)HJ MN?>ZW%F\VNL>^4]8L0B;8RZX47:L:-2\EFO7(S6O%AS.+F33U[]RM\7VKQ]& MIR+,SA>.>1P0(#+/?I[.XCYN+_GO9?;S\1S'J]90TDR)B?*0*G'B_&!\CB?R M<8*XP9"%.,&+7'G?_/+>[.XV"(3M3'%:9<(%TN7SY<94;/C]=P_=N9?B'"A_ M=YO@3<_;2/^@@#W@7V&Y=TZ4*6>K-N;@VO<@-RV3NQ5!('"BEFV?7RZ=!^K_ M]?TF>\;N*LP:WSY-TH_U'4CC[O7:?AK//)/&:XUC#VF[MSH7MG- W/ET,8RX M[?39 '-PJDXZHH*F_\PDS?54$/=FY,A-U[O^AA,2:4$PLH!AS M/XLR5ROUVD$3J;06/W:[GC,UX=GP]?)I^2YS=:F,7W\B[EN97,#* MV(GNIZ7R6;6U3;XT3QOM9H/\EPY'^Z1]7NNLD65R;C7QE7-@2O M3OJ'(G^G@Z-J)9HB<;E\P.JX(("Y!RL"^RN8#KHLT3>/2 A15\*)/EA; K4A M):1W_GKVN/B/5W&Q-99_)1*P\X+INL<]-XD+M"L3B<,#2;YW1WQ6!K[O3CGO MU\X6Q;\.V)\"=[#'E ^)92N9D7+0V^G&2U>#/0N" M2P'BC]U9Z/> K_BZ<)FU2"./J#%S)%?@4S93M[WJ];SZ[1]C46V>4Z\75^91 MO<4_PPKK\2^FXMC7M;>E+O<'ID^2K6D*D2GA]6F"'J\BA&CFA.B%"L[(4I-#%$ZG@8A3#/)L=,+"A_5:@"L MR8:D6 J_X6TM">K-G;Q1 N_D!\=$W(7R-"'D> 0I5HN0W%^"PDE+L#LCL)B2ODVZ3*1V "P0 M_)2%B*0QNW"+$VX3&">S[<45&"8V^X ?5?FG)BA0J)@N/!)V!V\RZ73F+5VX MRZ;O1[34S ?34A\IQ&L;=!]538UD8H+5U ^GI4:LQ-4ZU?,8;,3$V;X-+KTO M=$UDDJ5CI8BU5>_^_)%KQ">N34N/S6+)MYV8;]QJ#&O$]'L9KY3FZ\?W5+L4 M$?(J[,-N[*AFZ8%[-U6EQ9UZ&W5&(((1['8R2ID>+^P@\;)(#&,[>/KK0OBZ M.Y D&Z*B&4!';@"[X2@'+GEAS"M3#3=,SBG+(JOVT2O"/%=&QNF21\O&< P[ M6M;P3(97.; 1$%'J2=OVN(:!/QK6$!86)M>._; #UID]#D)YT>Z*A=I=Y"F[:R/!5X\\R8MA"'F)FI8/%%-3%D>RP7D8XVBD.";J1J:O,$)SLL#. M" S3IH)<,,]/#K3#5BM,1#;025;@ 7M9+APP!-42>?DN[C&9928"#9M(539( MHB[#<#(E!C.1T4#!!%Y']G1YRL^827+$!0+P\N/YCTBS=CZ'.\2V=UZZ3)&9 MS0N.=NBZ9U )=:4CEB9TYRR"B7E'9+;NNE!=AHW$WB]B0$NNF;K1:E:'Q%"2 M&1,#7?H\F^JYW/? !.+,*;".,@F>6%O) MG'#?.&:3\IQTG?<+]C/J8YXTTI)B:-R.OG%3[G@^ZL3U!CA>!O_^A366+1-L MS)AK3>,)@*>B,H^ EHU;6\9/704(51>,]R'.S%3W=?W[,(RC,^%JX#9F5Y)T M\CNA8PHQV;N$0U4)4P!UG2O4P('YO,J<_UMLQVLB.2$[:#L MJ,ER@ 6L;2S@E:<_+LQXL640AXZ?#M82G5S/WS@X=VNBB">6DIMDBUUX,JWF MTJKL;VR5D2N9(,YCE(LI9J>$<6/RVJVF0M@AJ&WK5(UFK0$YY M1CSNIM+RZ\LYSAWS=W_G;MGE$Z9#CT_E%:T,R$^7B%RO^?=$N#TC\2EB4EV9 MB8BN\.<&U,= _0V2^AWJ"0R<<80U5]66/A7_9(6D$,VB/8Z,\ ;(1$F"3\8T M+4/L43+0,3J8C;-"0D@.S&'\L.P-,42W17D@LQ[H2VZ@1M,-SE:C/I]^4H@_ M-Z5G(\37F03?*_P?AP*%M)"L-=KO;PFC@#^H@,T24*BIBJPR#O:/HU:=U%0L M6R:J@TG_,1Q2#\Z>99+]0UYKB)YEJDBNK>C MUV7U%BO5?W1BK52/-\2ZBL1:F=[KO:%5AU;KI:,-K:XBK=9IERD;,G7(]*)5 MW9#I*I+IA2>W84.MG%IS&TK]@Y1:QGAG#C4OQL*#\:F==U*A)B5X93K9FN;= M>NHJV#1NT[?DN 4^A9/R[Y>+?:+FZGL+X8\X-.^?V+&O5E=RC=,I$!W Q])5 M.R_L/>#TTMJQV0]6E6M3._:%\_+[M6-_-T;?K1&V B'Z:R,&UC.A!01RNW;2 M*'4N6]7V)B]G=6YWNG .PF-N>JY=,6IZA^WL!-TNT+DES:Z;GMVLZRO%!:^% M8M:^)FK^+FW)PIO1J%-M@J?B\4)'=DJSG22-Z?]8M[;+!E3IN95F>-TO-XN: M7T!EJ? 5[Y!:YD#C1;Z6FX3G+D,F ^NP21MZBUR,-[+& &M\^CF>>?&$1@EA MN],J?3^JMEI7Y+A6K5?:Q*GYW"@GO7"O3J[,QUJ?2%-,(L]:HWM@4_HATLB)* M:06+F.YY;VA>WG5\7J-X];U:?]+]GMLG35[GP-@C=;Q$?N.-?ZDW?HUN@HBT M=,T[=(LO5CUPZ&#Q=IDV TSY[<]D+(WW2:W"?[A.[QY=P_=,M8O<(RWPS]B7 M\?'-M_39PTWIZZ":^MJBDQ>2;UI5YU;JZJ^G%$ZLZG/SZV;I(W5A? MS9MV5C;TDG%>_+_S:OVT1K\?W_VLW)Q/^E\RF7I;*/;[BCHZ;:DWI9QA7=X- M?AS5[X]NU._?[GOWG=T';?>H?U6^JHRN\D>%LW$VMW-T]O6R<"+>C"ZO\J6[ MTTMA8(V[K6^[J9IZFSD6!J;4W[GZUOVBT(;5%^Y3=U7U1Z$]8MUOWUBFI;9/ MNE]OSK[>]QY.OK3.CT]V=/TH=?KMZ[?CVYIVMR-?=IK2B56AJ9TTK>_>_CHQ MC:^CK%[H%4].'Y33]JCZV9Z15%>3)OC_@3E4#O\?4$L#!!0 ( !1(J%@5 M-0^J+ , .D+ 1 =&-B<"TR,#(S,3(S,2YXVI?*24RP<.S4=KCTZVLG<;@$6* MXL&9.>?,C#WC MI'6W# F8(RXPHVVK4BI; %&/^9@&;>MQ;'\<=WH]"]S=OGT#U*_USK9!%R/B M-\$]\^P>G; ;\!6&J F^((HXE(S?@"=(8FUA74P0!QT61@1)I!QII":X*E6K M+K#M$W2?$/49?QSUBY+'P-,&QA#(6N5IY6H5FT_GSIX8["NNU MU8"&PCY\_?@VX:LB6\*0HA4(=!1=O2]67E+6HEQ@.G6BY7G)=! M?YS@K!387!),9_O@E4:CX21> RT@ERXG1KKF:+<+!%MZ7 M.6$3?.6DSBTHW@NMIU!LH#[:P0GDE0(V=Y1#X:LU XR%'4 8Y> )%&XBFCFV MP(++(E 9=T&V7$5([(6FKBW"0^?3,,=*S\4LFD(>ZJY, MWJ,)C(E*Y5<,"9Y@Y%M 0AX@J=M,1-!#K^J9;H64,M74:K(RB[9%$59=FQN4 M29]RDS."'E3Z0"_45!T*HMU.AZF[P0+8;UOIQ_@(X[2 ,/CT$_5%P:=@+NJ 8?%\+M)Q432W_ %!+ P04 " 4 M2*A8]IZ8N+L+ #CD %0 '1C8G M,C R,S$R,S%?;&%B+GAM;,V=86_; MN!G'WP_8=^"\-QM0QXV##4BNN4/JQ@?C(T(C%"=V< MC[XNQQ?+V6(Q0EF.:8Q31LGYB++13S_^\0](_/GTI_$8S1.2QF?H"XO&"[IF M/Z!KO"5GZ&=""<> S]+>CZ72%QN,! M^7XC-&;\Z]VBSO7EB+)G_,+X8W84L>VP#)3_[YZ]4R>B!; M/$ZH/&\1&:DHF8LM[OCT]'12I"JIH=RO>*J.<3)1=NJ<16K2H6\XR9*SK+!W MQ2*<%]7>>Q@$*N3_QDHVEE^-CZ?CD^.C?1:/U,DOSB!G*;DC:U04\RQ_?1(H M98DD851]]\#)VFXFY7PBXR>4;'!.8GF@4WF@X[_+ _VY^OH*KT@Z0E(I^ #+ M==K*JPJ:N#9[2WC"XDOZ/M=ZM"?[XK?#\_^A ,UXYT6X9SE.WV6^&>G<]C5Y MWQD_Q+D_TZ*=)^\[TXW(_XOMW+3\YM-K/Z^I_/)*?&I9)/M<=& D5B9E%ATM M<'&$HF.H\JYS9U$KWU2VYHR;99<]8Y%G1J*C#7N>Q"01>4]/Y(>Q_% 46_SG M]QD3(X&+599S'.4JIZ(8YR-+^D2W))477/G"/.HI7*681$QT34_Y."U/8QF^ MYFQK/6Q5:F9)_#U=U?'E:1&' (RV9)QD;,MQ" JV>9(K^5:@Z3(5S5_(5G$ MDROO9"82A=3&501$#V@.9*2)0%1(.-I?/WJD!C"H$"!W(&PE &*F2+$ M*S#_(I@/PZ6A] .+8=6.2BT+$!3=6Q\F4N\%DMF.\Y9KN,>!IRO:8K9_/ M KH@0.DQ9SRU+>4M4#SU0)K==$6XIG"EQQ09D3C&AIP?! F!* M9Z"4(:E#I=!+S:NG!#27DQC!XN@RMP383;8I:&L"(L%J#*#AH"WFE'HA8B9: M)H[3!8W)_A?R"I;+T+EE K#9AD(3!42%W1F 125&A1H)N1 \EH-XM+#VV MV\P XH#0Z78($"2"4#O*)T@+&C'^Q!K3'69L)QK UQF+X1%*3Y1;J 85H8U6 M9TA @ WQ"6#6"OU0SDE!3*[C*3) ,@:^Q<6"#0G M;RCJB7]H3H9"V9B8^WO![]F*;G TJO2!C6K4"Q)2:\"!I&^MM7$JU3R1N69;C]-_)4^>%N%WL!0^K M82LD+65XJ-CL]0%3QB 1Y./"NL)5/M"P+B73TMTM ;;8.BP!;B0& 8'-D;D$ MN+Q[4HI<5[-DE!,,M CM9&>5;#%5UW$C+8PJ-@T9-5S\KH7&QP]9[NZ2WCXP M"D\0,"6N:AHRIVI;3P^BQ@%3>JT7,E3H/-V-ESM,9/;FNY'FK&?7[=0=N4H( MHG9U-T8WK=(=U^9O/,G%D6=LN]W1ZBF/;=X@H'-5RYTV58U;14'4?I< M2 B)J(AB$:#<6(C?K-?6WKY+[ J*?L,*#E@9!"2]]G181, X:D2@,@05,7ZQ M6639CO WP6,)\800:!X R="'B!-DLA>J,M G6TL2[43_^'H\7=TG>6J[N#0E MSOHDP%S=(VGI0; !F-)9*-(06Z/CZ5]6?T4JRG'U7[-[CN7FLU MZ1\$;+P- C8]@X!-B(. S=!!P,;;($ =MMPB1+1+-ZLTV6!@<\).M6LH.BSK M?%BD0:$"^P/;C#H$'6)<[VA9;'$FM^?GV^+X<_'!4DI YVQ/RRZ;]::6-E$0 MC'0Y,[:U+#>=:XB15+OF8A\/<4;+0/,U.#WZ M,!@:9M+ J0Q3>QG6@8>M+EW?2B\G8/Q&TO07RE[HDN",41*7]U)L3XJZ]6YG MS/38;D^: <1!X#3$(3!U1@:-'V444F'5G3 O)'UCZ8[FF!=KR;FM90)T;LD! M;+:)T40!D6)W!A!2BU&I]K- N]P]HAYDE>\= @L(R1TOU^XTK:W:MFH#8J;3 M(+2&N]KSXS V+J,\+;',B7Q?1/),ON <5][ \D)RUXLJNTSKJREMVH 0ZC0( MKI^L8^16,5@QY6W+0ZT-ZY@EKJG<;QQC6#3WCJDE >%A\]6Q@PQ'2NN% MA>46I^GG7990DL$=D:9RRX+58IN%EB0@%FR^ !8**5):+RQ<;@G?B.[M9\Y> M\H=J?U:P;(#:+1N=EMN,6*4!L=+E#V!&A: R1FVIZP>>_6%#\7*71;BD%JEC M;$"S&C.&+B1@(',&+2F)Y/V6:Y:C>X:^9@3E#P1=5J^A:^X$7^;CZTTC4207 M1)2C/=(X8R")!Z[<'O(:DCD IQ3,V-8)@WK^,*$XN< M;,'5#OTAK@@::EYQU*,@S?96EI'.^89]K3-LL[" (BP'0% M;9%7"%&A]%+_GS%]Y+NG/'J]Y2PB1,ZRRNK6JN_^V\!HM\R\J4AMF@:%!L39 M6_P"!!ZR0(T\/C1Z+)\W\^2D<;F;&XL>EP]8G,";79[)'E08@^^"=P8Y?KPP MH #:0X:.B(#0&V 3>N!01*(B] ,J@U$CVM/U67;8!9#$GU_OR)IPN>[@GNSS MS^) CQU7& -B75^]#2Z.?C'7&Q@$A&]U"UWJ9:B9 5K).6)5%NB[S 05N;A^ M?_DB6O-B(@GC%WE.Q$^CF,1D7VW0)7:%7;]AQ1FL# *L7GLZ28O9_ Y5$:@1 MXF-!PN&](*)EWN:7G#,^8Z+[CCKP&1+D_MTL?04P7],"102!U6";'2]O,2:2 MH2(;=,@'?9EC04AU:;NT"K&(P%(ZK6+>F5;-* M#JFJ-4]0=2N9I7@ %0 '1C8G M,C R,S$R,S%?<')E+GAM;,VOI*=A"2VY,.-#UQ M<'[)^K]CRSZ6Y/,/RY1'SU1I)L5%JWMTW(JHB&7"Q/2B]774OASUA\-6I T1 M">%2T(N6D*T/?_W\4V1_SG]IMZ,!HSPYBS[*N#T4$_D^NB4I/8L^44$5,5*] MC[X1GKDMWIZVLF_ MW4A+RN58\#G!)7D](%.(O?71F^[5Q./F9S/B$I=R#KNZTY?VD/2MC4O M.%-TE,74?%>L,H'YUK1F1-E*VK',\:W<9XH MF?KHK$E(3T-W0=E=-$/STNX_<6T8<#*MQGD@ ?+L8@"M=(-%]"/5L6)SQZ4& M[)X2R+>'RK?"6\.8-^?. YTRUU[7%'?)I6YCN%_P% &"/\'L*8)ND2)P*41& M^ .=2U4#?E\)Y/T;)N\J;TB8_\Z(,E3Q%81T20R$_0X3ML%D-)/X[ZHV'QR,2\M&,GUGQLF:#<4BDHY>(P(+P ! MFV\$>^]UV'MP["AY:*W--X+]Y'783^#847+16IN8V/OVXYUZE O/"+17#$6. MDHO66,0$GE]I[M2]DL^LF!=51[U4 HH>,44-FT4]X(N+/.1HWRBAO!'3U6IS MF)SOI3:$_\?F=7>2U7HH<\3$-62TZ0>,1=S=0PO?5*(#"90O2JY:::=II"[" MBA+_X;NO@ )%24"KS#3,\T:ZL8^9%,'GL645E"M*)NDSU73'ZZ82:^^IO_,U M> 8;2K=Z:*-AC-\5,[8%?9FFF5@_H_&,BGFD4+PHZ5_07L.H1Y*SF!DFIE_L M':)BA%=SKM)!(:,D>WYC#1.^5]1%FMK;[GP>EUMKH.XF$U_/&])#B:/D>O5& M<BW_BE+0**"D?5#33?KW1*AU+[E\>4BF$$D9)\ +6&H:\UXYJO <2*%B4S*[2#E*?<+V, M9T1,J7_V0K42"A@ETPN90^M[IZ"^=_K*OA,S\0 M0FDC3H6MM(8">902SJ\RS035P;[E0 B%C#CGM=(:"N3KE*JI[=0^*;DPL_7: MSA!L3P$H=,29K4&K./"7+^O(B_5O0?(5:O#;"1"Q>TUBO78CCMU$BN)*+A*B M/-1#>BAWU(65?J,-D[\S,ZIV[Y_RQ@QMWA::]%!?"AH%E'05:AKGVKJSDC]X M:=W307DC)J95QG#63&5CSN(!ER1X7[XG@_)%S$(K;*'@O2+B265S$Z_NE8PI M=<,G>GNV 1(B8 70D"#FIZ]"@?.X0*:I6TPDXZ?1S)K6=YG)WV!JVQ=\:! L M!PT-YB).@'&DNR#]LM"+)E>K!SJARDU3>*1+# MO%F_OSL(]$4$A8HWUEJV5 'VO%-J_8W=8+]=?^-^N9>1VRW_ U!+ 0(4 Q0 M ( !1(J%AV02P#I0< XO * " 0 !E>#,Q+3$N M:'1M4$L! A0#% @ %$BH6-AU2=V?!P FBX H ( ! MS0< &5X,S$M,BYH=&U02P$"% ,4 " 42*A89-<%I6<% #!)@ "@ M @ &4#P 97@S,BTQ+FAT;5!+ 0(4 Q0 ( !1(J%A0#F?F M7Q\ -P% 0 - " 2,5 !F;W)M,3 M:V$N:'1M4$L! A0# M% @ %$BH6!4U#ZHL P Z0L !$ ( !K30 '1C8G M M,C R,S$R,S$N>'-D4$L! A0#% @ %$BH6/:>F+B["P XY !4 M ( !"#@ '1C8G M,C R,S$R,S%?;&%B+GAM;%!+ 0(4 Q0 ( M !1(J%ARBI<_OP< -Y> 5 " ?9# !T8V)P+3(P,C,Q A,C,Q7W!R92YX;6Q02P4& < !P"H 0 Z$L end XML 19 form10-ka_htm.xml IDEA: XBRL DOCUMENT 0001782430 2023-01-01 2023-12-31 0001782430 2023-06-30 0001782430 2024-05-08 iso4217:USD shares iso4217:USD shares true FY 0001782430 10-K/A true 2023-12-31 --12-31 2023 false 001-41628 STRAWBERRY FIELDS REIT, INC. MD 84-2336054 6101 Nimtz Parkway South Bend IN 46628 (574) 807-0800 Common stock STRW NYSE No No Yes Yes Non-accelerated Filer true true false false false false 38040290000000 6440509 400 HACKER, JOHNSON & SMITH PA Tampa, Florida Strawberry Fields REIT, Inc. (the “Company”) is amending its Annual Report on Form 10-K to add Management’s Annual Report on Internal Control Over Financial Reporting to Part II, Item 9A.